open access

Vol 27, No 2 (2022)
Review paper
Early publication date: 2022-03-07
Get Citation

Tailored treatment strategies for cancer patients during COVID-19 pandemic

Haytham Abdelkader1, Mohamed El Kassas2
DOI: 10.5603/RPOR.a2022.0024
·
Rep Pract Oncol Radiother 2022;27(2):318-330.
Affiliations
  1. Clinical Oncology Department, Faculty of Medicine, Helwan University, Cairo, Egypt
  2. Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt

open access

Vol 27, No 2 (2022)
Reviews
Early publication date: 2022-03-07

Abstract

The global pandemic of respiratory disease caused by the novel human coronavirus (SARS-CoV-2) has caused indefinite global distress, uncertainty, and disturbance. This pandemic has had direct and indirect impacts for the healthcare systems across the world, but certain subgroups of patients have been particularly affected. Among these groups are patients with cancer, who as a result of their immunosuppressed status either from the disease itself or as a consequence of treatment, are at increased risk of severe COVID-19 infection and complications. The pandemic has also led to limited resources as medical services have been primarily directed to emergency care. In this context, physicians and healthcare providers have had to balance the importance of continuing treatment of cancer patients with the risk of virus infection.    

In this review, we outline the treatment strategies for cancer patients during this pandemic, focusing on tailored treatment in this challenging situation of varying risks and benefits.

Abstract

The global pandemic of respiratory disease caused by the novel human coronavirus (SARS-CoV-2) has caused indefinite global distress, uncertainty, and disturbance. This pandemic has had direct and indirect impacts for the healthcare systems across the world, but certain subgroups of patients have been particularly affected. Among these groups are patients with cancer, who as a result of their immunosuppressed status either from the disease itself or as a consequence of treatment, are at increased risk of severe COVID-19 infection and complications. The pandemic has also led to limited resources as medical services have been primarily directed to emergency care. In this context, physicians and healthcare providers have had to balance the importance of continuing treatment of cancer patients with the risk of virus infection.    

In this review, we outline the treatment strategies for cancer patients during this pandemic, focusing on tailored treatment in this challenging situation of varying risks and benefits.

Get Citation

Keywords

COVID-19; cancer; tailored treatment; chemotherapy; radiation therapy

About this article
Title

Tailored treatment strategies for cancer patients during COVID-19 pandemic

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 27, No 2 (2022)

Article type

Review paper

Pages

318-330

Early publication date

2022-03-07

Page views

911

Article views/downloads

47

DOI

10.5603/RPOR.a2022.0024

Bibliographic record

Rep Pract Oncol Radiother 2022;27(2):318-330.

Keywords

COVID-19
cancer
tailored treatment
chemotherapy
radiation therapy

Authors

Haytham Abdelkader
Mohamed El Kassas

References (109)
  1. Killerby ME, Biggs HM, Haynes A, et al. Human coronavirus circulation in the United States 2014-2017. J Clin Virol. 2018; 101: 52–56.
  2. Harky A, Chiu CM, Yau TH, et al. Cancer Patient Care during COVID-19. Cancer Cell. 2020; 37(6): 749–750.
  3. Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol. 2020; 43(6): 452–455.
  4. Rakhsha A, Azghandi S, Taghizadeh-Hesary F. COVID-19 pandemic and patients with cancer: The protocol of a Clinical Oncology center in Tehran, Iran. Rep Pract Oncol Radiother. 2020; 25(5): 765–767.
  5. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335–337.
  6. Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2021; 7(2): 220–227.
  7. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020; 21(8): 1023–1034.
  8. Zadnik V, Mihor A, Tomsic S, et al. Impact of COVID-19 on cancer diagnosis and management in Slovenia - preliminary results. Radiol Oncol. 2020; 54(3): 329–334.
  9. Celayir MF, Aygun N, Tanal M, et al. How should be the Surgical Treatment Approach during the COVID-19 Pandemic in Patients with Gastrointestinal Cancer? Sisli Etfal Hastan Tip Bul. 2020; 54(2): 136–141.
  10. Liu Z, Zhang Y, Wang X, et al. Recommendations for Surgery During the Novel Coronavirus (COVID-19) Epidemic. Indian J Surg. 2020 [Epub ahead of print]: 1–5.
  11. Aygun N, Iscan Y, Ozdemir M, et al. Endocrine Surgery during the COVID-19 Pandemic: Recommendations from the Turkish Association of Endocrine Surgery. Sisli Etfal Hastan Tip Bul. 2020; 54(2): 117–131.
  12. Ngaserin SHN, Koh FH, Ong BC, et al. COVID-19 not detected in peritoneal fluid: a case of laparoscopic appendicectomy for acute appendicitis in a COVID-19-infected patient. Langenbecks Arch Surg. 2020; 405(3): 353–355.
  13. Hadjittofi C, Seraj SS, Uddin A, et al. Laparoscopic vs open surgery during the COVID-19 pandemic: what are the risks? Ann R Coll Surg Engl. 2021; 103(5): 354–359.
  14. Zheng MH, Boni L, Fingerhut A. Minimally Invasive Surgery and the Novel Coronavirus Outbreak: Lessons Learned in China and Italy. Ann Surg. 2020; 272(1): e5–e6.
  15. Vigneswaran Y, Prachand VN, Posner MC, et al. What Is the Appropriate Use of Laparoscopy over Open Procedures in the Current COVID-19 Climate? J Gastrointest Surg. 2020; 24(7): 1686–1691.
  16. Allaix ME, Lo Secco G, Velluti F, et al. Colorectal surgery during the COVID-19 outbreak: do we need to change? Updates Surg. 2021; 73(1): 173–177.
  17. Tseng LN, Berends FJ, Wittich P, et al. Port-site metastases. Impact of local tissue trauma and gas leakage. Surg Endosc. 1998; 12(12): 1377–1380.
  18. Brundell SM, Tucker K, Texler M, et al. Variables in the spread of tumor cells to trocars and port sites during operative laparoscopy. Surg Endosc. 2002; 16(10): 1413–1419.
  19. Liu Z, Ding Z, Guan Xu, et al. Optimizing response in surgical systems during and after COVID-19 pandemic: Lessons from China and the UK - Perspective. Int J Surg. 2020; 78: 156–159.
  20. Francis N, Dort J, Cho E, et al. SAGES and EAES recommendations for minimally invasive surgery during COVID-19 pandemic. Surg Endosc. 2020; 34(6): 2327–2331.
  21. Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020; 181(3): 487–497.
  22. Dowsett M, Ellis MJ, Dixon JM, et al. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. NPJ Breast Cancer. 2020; 6: 21.
  23. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020; 172(9): 577–582.
  24. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020; 323(14): 1406–1407.
  25. O'Leary MP, Choong KC, Thornblade LW, et al. Management Considerations for the Surgical Treatment of Colorectal Cancer During the Global Covid-19 Pandemic. Ann Surg. 2020; 272(2): e98–e9e105.
  26. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335.
  27. Young BE, Ong SW, Kalimuddin S, et al. Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020; 323(15): 1488–1494.
  28. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020; 382(12): 1177–1179.
  29. Chen WJ, Yang JY, Lin JH, et al. Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. Clin Infect Dis. 2006; 42(11): 1561–1569.
  30. Santarpia J, Rivera D, Herrera V, et al. Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. medRxiv. .
  31. Day AT, Sher DJ, Lee RC, et al. Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. Oral Oncol. 2020; 105: 104684.
  32. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6): 783–791.
  33. Giannakoulis VG, Papoutsi E, Siempos II. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob Oncol. 2020; 6: 799–808.
  34. Kuderer NM, Choueiri TK, Shah DP, et al. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241): 1907–1918.
  35. American Society for Radiation Oncology. COVID-19 recommendations and information: COVID-19 clinical guidance. 2020. https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information/Clinical-Guidance (August 3, 2020).
  36. Yahalom J, Dabaja BS, Ricardi U, et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood. 2020; 135(21): 1829–1832.
  37. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012; 13(6): 579–588.
  38. Zou XC, Wang QW, Zhang JM. Comparison of 5-FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis. Clin Colorectal Cancer. 2017; 16(3): e123–e139.
  39. Shereen NG, Salman D. Delivering chemotherapy at home: how much do we know? Br J Community Nurs. 2019; 24(10): 482–484.
  40. American Society of Hematology. COVID-19 and hodgkin lymphoma: frequently asked questions. 2020. https://www.hematology.org/covid-19/covid-19-and-hodgkin-lymphoma (August 3, 2020).
  41. Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. J Clin Oncol. 2020; 38(30): 3538–3546.
  42. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020; 190(5): e279–e282.
  43. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020; 217(6).
  44. Dumoulin DW, Gietema HA, Paats MS, et al. Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis. Front Oncol. 2020; 10: 577696.
  45. Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020; 141: 92–104.
  46. Thomson DJ, Yom SS, Saeed H, et al. Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. Int J Radiat Oncol Biol Phys. 2020; 108(2): 379–389.
  47. Lancia A, Bonzano E, Bottero M, et al. Radiotherapy in the era of COVID-19. Expert Rev Anticancer Ther. 2020; 20(8): 625–627.
  48. Malicki J, Martenka P, Dyzmann-Sroka A, et al. Impact of COVID-19 on the performance of a radiation oncology department at a major comprehensive cancer centre in Poland during the first ten weeks of the epidemic. Rep Pract Oncol Radiother. 2020; 25(5): 820–827.
  49. Parashar B, Chen WC, Herman JM, et al. Disease Site-Specific Guidelines for Curative Radiation Treatment During 'Limited Surgery' and 'Hospital Avoidance': A Radiation Oncology Perspective From the Epicenter of COVID-19 Pandemic. Cureus. 2020; 12(5): e8190.
  50. Chen WC, Teckie S, Somerstein G, et al. Guidelines to reduce hospitalization rates for patients receiving curative-intent radiation therapy during the COVID-19 pandemic: report from a multicenter New York area institution. Adv Radiat Oncol. 2020; 5(4): 621–627.
  51. Thomson D, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiother Oncol. 2020; 151: 314–321.
  52. Wu JA, Rimner A, Shepherd AF, et al. Thoracic radiation therapy during COVID-19: provisional guidelines from a comprehensive cancer center within a pandemic epicenter. Adv Radiat Oncol. 2020; 5(4): 603–607.
  53. Romesser PB, Wu AJ, Cercek A, et al. Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center. Adv Radiat Oncol. 2020; 5(4): 687–689.
  54. Spencer K, Jones C, Girdler R, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol. 2021; 22(3): 309–320.
  55. Braunstein LZ, Gillespie EF, Hong L, et al. Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints-Approaches to Defer or Shorten Treatment From a Comprehensive Cancer Center in the United States. Adv Radiat Oncol. 2020; 5(4): 582–588.
  56. Solin LJ, Gray R, Hughes LL, et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015; 33(33): 3938–3944.
  57. McCormick B. RTOG 9804: A prospective randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiation (RT) to observation (OBS). J Clin Oncol. 2012; 30(15_suppl): 1004–1004.
  58. Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Ann Surg Oncol. 2016; 23(12): 3801–3810.
  59. Haviland J, Owen J, Dewar J, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11): 1086–1094.
  60. Agrawal RK, Alhasso A, Barrett-Lee PJ, et al. FAST Trialists group. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011; 100(1): 93–100.
  61. Brunt AM, Wheatley D, Yarnold J, et al. FAST-Forward Trial Management Group. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016; 120(1): 114–118.
  62. National Comprehensive Cancer Network. Rectal Cancer. NCCN Guidelines Version 2020.
  63. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93(10): 1215–1223.
  64. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012; 30(31): 3827–3833.
  65. Marijnen CAM, Peters FP, Rödel C, et al. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol. 2020; 148: 213–215.
  66. Faivre-Finn C, Fenwick JD, Franks KN, et al. Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic. Clin Oncol (R Coll Radiol). 2020; 32(8): 481–489.
  67. Liao Z, Rivin Del Campo E, Salem A, et al. Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer. 2020; 146: 230–235.
  68. Manyam BV, Videtic GMM, Verdecchia K, et al. Effect of Tumor Location and Dosimetric Predictors for Chest Wall Toxicity in Single-Fraction Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2019; 9(2): e187–e195.
  69. Ma JT, Liu Y, Sun Li, et al. Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies. Int J Radiat Oncol Biol Phys. 2019; 103(4): 843–850.
  70. Andolino DL, Forquer JA, Henderson MA, et al. Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys. 2011; 80(3): 692–697.
  71. Asai K, Shioyama Y, Nakamura K, et al. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship. Int J Radiat Oncol Biol Phys. 2012; 84(3): 768–773.
  72. Bongers EM, Haasbeek CJA, Lagerwaard FJ, et al. Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. J Thorac Oncol. 2011; 6(12): 2052–2057.
  73. Prewett SL, Aslam S, Williams MV, et al. The management of lung cancer: a UK survey of oncologists. Clin Oncol (R Coll Radiol). 2012; 24(6): 402–409.
  74. Hamdy FC, Donovan JL, Lane JA, et al. ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016; 375(15): 1415–1424.
  75. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015; 33(3): 272–277.
  76. Serrano NA, Anscher MS. Favorable vs unfavorable intermediate-risk prostate cancer: a review of the new classification system and its impact on treatment recommendations. Oncology. 2016; 30(3): 229–236.
  77. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016; 17(8): 1047–1060.
  78. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016; 17(8): 1061–1069.
  79. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299(3): 289–295.
  80. Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015; 33(4): 332–339.
  81. Zaorsky NG, Yu JB, McBride SM, et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Adv Radiat Oncol. 2020; 5(4): 659–665.
  82. Care of Prostate Cancer Patients During the COVID-19 Pandemic: Recommendations of the NCCN . https://www.nccn.org/covid-19/pdf/NCCN_PCa_COVID_guidelines.pdf.
  83. Zaorsky NG, Yu JB, McBride SM, et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Adv Radiat Oncol. 2020; 5(4): 659–665.
  84. Fransson P, Nilsson P, Gunnlaugsson A, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196): 385–395.
  85. Zaorsky NG, Ohri N, Showalter TN, et al. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev. 2013; 39(7): 728–736.
  86. Koontz BF, Bossi A, Cozzarini C, et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015; 68(4): 683–691.
  87. Yong JHe, Mainprize JG, Yaffe MJ, et al. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada. J Med Screen. 2021; 28(2): 100–107.
  88. Yin K, Singh P, Drohan B, et al. Breast imaging, breast surgery, and cancer genetics in the age of COVID-19. Cancer. 2020; 126(20): 4466–4472.
  89. Miller MJ, Xu L, Qin J, et al. Impact of COVID-19 on Cervical Cancer Screening Rates Among Women Aged 21-65 Years in a Large Integrated Health Care System - Southern California, January 1-September 30, 2019, and January 1-September 30, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70(4): 109–113.
  90. ASCO. COVID-19 Vaccine and patients with cancer. https://www.asco.org/covid-resources/vaccines-patients-cancer.
  91. NCCN: Cancer and COVID-19 Vaccination Version 1.0 1/22/2021. www.nccn.org/covid-19/pdf/COVID-19_Vaccination.
  92. Lee L, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241): 1919–1926.
  93. Rogiers A, Pires da Silva I, Tentori C, et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021; 9(1).
  94. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335–337.
  95. Ueda M, Martins R, Hendrie PC, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020: 1–4.
  96. Schwamm LH, Erskine A, Licurse A. A digital embrace to blunt the curve of COVID19 pandemic. NPJ Digit Med. 2020; 3: 64.
  97. Canadian Medical Association Virtual Care In Canada: Discussion paper. CMA Health Summit. https://www.cma.ca/sites/default/files/pdf/News/Virtual_Care_discussionpaper_v2EN.pdf (2020-11-13).
  98. Selby P, Popescu R, Lawler M, et al. The Value and Future Developments of Multidisciplinary Team Cancer Care. Am Soc Clin Oncol Educ Book. 2019; 39: 332–340.
  99. Levine OH, McGillion M, Levine M. Virtual Cancer Care During the COVID-19 Pandemic and Beyond: A Call for Evaluation. JMIR Cancer. 2020; 6(2): e24222.
  100. Bitar N, Kattan J, Kourie HR, et al. The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic. Future Oncol. 2020; 16(11): 615–617.
  101. ESMO. Cancer patient management during the COVID-19 pandemic (2020). www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic.
  102. ESMO. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer (2020). www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era.
  103. Yildiz F, Oksuzoglu B. Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors? Future Oncol. 2020; 16(28): 2191–2195.
  104. Tasneem S, Kim A, Bagheri A, et al. Telemedicine Video Visits for patients receiving palliative care: A qualitative study. Am J Hosp Palliat Care. 2019; 36(9): 789–794.
  105. Raskin Jo, Lebeer M, De Bondt C, et al. Cancer in the time of COVID-19: expert opinion on how to adapt current practice. Eur Respir J. 2020; 55(5).
  106. Cox A, Lucas G, Marcu A, et al. Cancer Survivors' Experience With Telehealth: A Systematic Review and Thematic Synthesis. J Med Internet Res. 2017; 19(1): e11.
  107. Larson JL, Rosen AB, Wilson FA. The Effect of Telehealth Interventions on Quality of Life of Cancer Patients: A Systematic Review and Meta-Analysis. Telemed J E Health. 2018; 24(6): 397–405.
  108. Hennemann-Krause L, Lopes AJ, Araújo JA, et al. The assessment of telemedicine to support outpatient palliative care in advanced cancer. Palliat Support Care. 2015; 13(4): 1025–1030.
  109. Smrke A, Younger E, Wilson R, et al. Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. JCO Glob Oncol. 2020; 6: 1046–1051.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl